Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm, cytosol. Endosome membrane Peripheral membrane protein Note=Localizes to the midbody of dividing cells. Localized in two distinct rings on either side of the Fleming body. |
Domain |
PF03357 Snf7 |
Function |
Probable peripherally associated component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release. |
Biological Process |
GO:0000070 mitotic sister chromatid segregation GO:0000226 microtubule cytoskeleton organization GO:0000819 sister chromatid segregation GO:0000920 cell separation after cytokinesis GO:0001881 receptor recycling GO:0001919 regulation of receptor recycling GO:0006900 membrane budding GO:0006997 nucleus organization GO:0007032 endosome organization GO:0007033 vacuole organization GO:0007034 vacuolar transport GO:0007040 lysosome organization GO:0007041 lysosomal transport GO:0007051 spindle organization GO:0007059 chromosome segregation GO:0007067 mitotic nuclear division GO:0007080 mitotic metaphase plate congression GO:0007088 regulation of mitotic nuclear division GO:0007098 centrosome cycle GO:0007346 regulation of mitotic cell cycle GO:0008333 endosome to lysosome transport GO:0010824 regulation of centrosome duplication GO:0016050 vesicle organization GO:0016197 endosomal transport GO:0019058 viral life cycle GO:0019068 virion assembly GO:0031023 microtubule organizing center organization GO:0032886 regulation of microtubule-based process GO:0032984 macromolecular complex disassembly GO:0036257 multivesicular body organization GO:0036258 multivesicular body assembly GO:0043112 receptor metabolic process GO:0043241 protein complex disassembly GO:0044803 multi-organism membrane organization GO:0046605 regulation of centrosome cycle GO:0046755 viral budding GO:0050000 chromosome localization GO:0051225 spindle assembly GO:0051297 centrosome organization GO:0051298 centrosome duplication GO:0051303 establishment of chromosome localization GO:0051310 metaphase plate congression GO:0051493 regulation of cytoskeleton organization GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0051783 regulation of nuclear division GO:0070507 regulation of microtubule cytoskeleton organization GO:0071985 multivesicular body sorting pathway GO:0080171 lytic vacuole organization GO:0090169 regulation of spindle assembly GO:0090224 regulation of spindle organization GO:0090307 mitotic spindle assembly GO:0098813 nuclear chromosome segregation GO:1901673 regulation of mitotic spindle assembly GO:1902115 regulation of organelle assembly GO:1902590 multi-organism organelle organization GO:1902592 multi-organism membrane budding GO:1902850 microtubule cytoskeleton organization involved in mitosis GO:1904896 ESCRT complex disassembly GO:1904903 ESCRT III complex disassembly |
Molecular Function |
GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion |
Cellular Component |
GO:0005913 cell-cell adherens junction GO:0010008 endosome membrane GO:0044440 endosomal part |
KEGG |
hsa04144 Endocytosis |
Reactome |
R-HSA-162588: Budding and maturation of HIV virion R-HSA-1643685: Disease R-HSA-917729: Endosomal Sorting Complex Required For Transport (ESCRT) R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-5663205: Infectious disease R-HSA-162599: Late Phase of HIV Life Cycle R-HSA-199991: Membrane Trafficking R-HSA-5653656: Vesicle-mediated transport |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CHMP5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CHMP5 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CHMP5 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CHMP5 in various data sets.
|
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHMP5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHMP5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHMP5. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHMP5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CHMP5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CHMP5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CHMP5 |
Name | charged multivesicular body protein 5 |
Aliases | HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ...... |
Chromosomal Location | 9p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CHMP5 collected from DrugBank database. |
There is no record. |